Abstracts Archive - Page 1157 of 2425 - ACR Meeting Abstracts

Abstract Number: 2287 • 2018 ACR/ARHP Annual Meeting
Interim Results of an Open-Label Study Assessing Efficacy and Safety of Adrenocorticotropic Hormone Gel for Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
Anthony Fernandez, Dermatology and Pathology, Cleveland Clinic, Cleveland, OH
Background/Purpose: Cutaneous dermatomyositis (DM) is often refractory to multiple medications, suggesting better treatments are needed. Adrenocorticotropic hormone gel is a repository corticotropin injection that is…
Abstract Number: 2288 • 2018 ACR/ARHP Annual Meeting
Preexisting Anti-Acetylcholine Receptor Autoantibodies and B Cell Lymphopenia Are Associated with the Development of Myositis in Thymoma Patients Treated with Avelumab, an Immune Checkpoint Inhibitor Targeting Programmed Death-Ligand 1
Andrew Mammen¹, Arun Rajan², Katherine Pak¹, Tanya Lehky³, Livia Casciola-Rosen⁴, Renee Donahue², Lauren Lepone², Anastasia Zekeridou⁵, Sean Pittock⁵, Raffit Hassan², Jeffrey Schlom² and James Gulley², ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²NCI, NIH, Bethesda, MD, ³NINDS, NIH, Bethesda, MD, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Neurology, Mayo Clinic, Rochester, MN
Background/Purpose: Immune checkpoint inhibitors (ICIs) enhance the immune response against tumors but may also trigger immune-related adverse events (IRAEs). Myositis following receipt of ICIs is…
Abstract Number: 2289 • 2018 ACR/ARHP Annual Meeting
Granulomatous Myositis: Heterogeneity and Response to Treatment
Yannick Dieudonné¹, Yves Allenbach², Olivier Benveniste³, Sarah Leonard-louis⁴, Baptiste Hervier², Kuberaka Mariampillai³, Beatrice Lannes⁵, Daniel Wendling⁶, Christan Von Frenckell⁷, Nicolas Poursac⁸, Emmanuel Mortier⁹, Christian Lavigne¹⁰, Olivier Hinschberger¹¹, Julie Magnant¹², Bernard Geny¹³, Jean Sibilia¹⁴ and Alain Meyer¹⁵, ¹Département d’Immunologie Clinique et Médecine Interne, Centre de Référence des Maladies Auto-immunes Rares, Hôpitaux Universitaires de Strasbourg, STRASBOURG, France, ²Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, ³Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Neuro-Musculaires Paris Est, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Universitaire Pitié-Salpêtrière, Paris, France, ⁴Département de Neuropathologie, Centre de Référence des Maladies Neuro-Musculaires Paris Est, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Universitaire Pitié-Salpêtrière, Paris, France, ⁵Département de Pathologie, Hôpitaux Universitaires de Strasbourg, STRASBOURG, France, ⁶Rheumatology, University Hospital - Bourgogne Franche Comté University, Besançon, France, ⁷Département de Rhumatologie, Hôpital Universitaire Sart-Tilman, Liège, Belgium, ⁸9Departement de Rhumatologie, Hôpital Universitaire de Bordeaux, Bordeaux, France, ⁹Departement de Médicine Interne, Hôpital Universitaire Louis Mourier, Colombes, France, ¹⁰Departement de Médicine Interne et Maladies Vasculaires, Hopital Universitaire d'Angers, Angers, France, ¹¹Departement de Médicine Interne, Hôpital Emile Muller, Mulhouse, France, ¹²Departement de Médicine Interne, Hôpital Universitaire de Tours, Tours, France, ¹³Institut de Physiologie EA 3072, Service de Physiologie et d’Explorations Fonctionnelles, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ¹⁴Département de Rhumatologie, Centre de Référence des Maladies Auto-immunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ¹⁵15Département de Rhumatologie, Centre de Référence des Maladies Auto-immunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Background/Purpose: Granuloma in the muscle can be found in patients with myopathy. This finding has alternatively been interpreted as either sarcoid myopathy or other myositis…
Abstract Number: 2290 • 2018 ACR/ARHP Annual Meeting
Long Term Follow-up Results of Myositis Patients Treated with H. P. Acthar Gel
Didem Saygin¹, Galina Marder², Chester V. Oddis³, Siamak Moghadam-Kia⁴, Preeya Nandkumar⁵, Zengbiao Qui⁶, Diane Koontz⁷ and Rohit Aggarwal⁸, ¹Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Rheumatology, Northwell Health, Manhasset, NY, ³Division of Rheumatology and Clinical Immunology, Department of Medicine, Unviersity of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Medicine-- Division of Rheumatology, Northwell Health, GREAT NECK, NY, ⁶Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷Internal Medicine Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Although HP Acthar gel is a purified, injectable formulation of full-length adrenocorticotropic hormone approved by the FDA for use in myositis, peer-reviewed data is…
Abstract Number: 2291 • 2018 ACR/ARHP Annual Meeting
Longitudinal Course of the Disease in Anti-Mi2 Patients: More Intense Muscle Weakness, Good Response to Treatment and Progressive Reduction of Autoantibody Titers
Iago Pinal-Fernandez^1,2, Katherine Pak³, Maria Casal-Dominguez^4,5, Wilson Huang⁴, Jemima Albayda⁶, Eleni Tiniakou⁷, Julie J. Paik¹, Christopher A. Mecoli⁸, Sonye K. Danoff⁹, Lisa Christopher-Stine⁹ and Andrew Mammen^3,10, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴NIAMS, NIH, Bethesda, MD, ⁵Johns Hopkins Medical School, Baltimore, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Internal Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, ⁹Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Autoantibodies targeting the Mi-2 (Mi-2a and Mi-2b) nuclear antigen in patients with dermatomyositis (DM) were first described in 1985. However, little is known about…
Abstract Number: 2292 • 2018 ACR/ARHP Annual Meeting
The Predictive Risk Factors for Opportunistic Infection during Immunosuppressive Therapy for Polymyositis/Dermatomyositis
Yumiko Sugiyama¹, Ryusuke Yoshimi², Maasa Tamura², Mitsuhiro Takeno³, Yohei Kirino², Shigeru Ohno⁴ and Hideaki Nakajima², ¹Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ²Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁴Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Although concomitant infectious diseases are the predominant causes of death in patients with polymyositis (PM)/dermatomyositis (DM), intensive immunosuppressive treatment are necessary for severe cases.…
Abstract Number: 2293 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Analysis of a Monocentric Cohort
Emanuele Calabresi¹, Simone Barsotti², Elisa Cioffi³, Alessandra Tripoli¹, Andrea Delle Sedie¹, Laura Bazzichi⁴, Ornella Mazzarella¹, Rossella Neri⁴ and Marta Mosca¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Department of Medical Biotechnologies, University of Siena, Siena, Italy, ³Rheumatology Unit, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴Rheumatology Unit, University of Pisa, PISA, Italy
Background/Purpose: Despite the absence of specific guidelines, the treatment with intravenous immunoglobulins (IvIg) is considered effective in patients with refractory idiopathic inflammatory myopathies (IIM). Recently,…
Abstract Number: 2294 • 2018 ACR/ARHP Annual Meeting
Improving EULAR/Acr Classification Criteria for Idiopathic Inflammatory Myopathies
Kylee Dawson¹, Chester V. Oddis², Siamak Moghadam-Kia², Diane Koontz², Nicole Niemen² and Rohit Aggarwal², ¹Internal Medicine, Department of Medicine, University of Pittsburgh Medical Center Mercy Hospital, Pittsburgh, PA, ²Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: New 2016 EULAR/ACR classification criteria have been established for idiopathic inflammatory myopathies (IIM). The highest weighted score is associated with the presence of anti-Jo-1…
Abstract Number: 2295 • 2018 ACR/ARHP Annual Meeting
Classification of Idiopathic Inflammatory Myopathies: Assessment of 123 Patients According to 2017 Acr/EULAR Criteria Followed up By a Single Center from Turkey
Emin Oguz¹, Ezgi Sahin², Murat Erdugan¹, Bahar Artim-Esen¹, Ahmet Gül¹, Lale Ocal¹ and Murat Inanc³, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey, ³Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey
Background/Purpose: The aim of this study is to evaluate sensitivity, limitations and assessment of 2017 ACR/EULAR IIMs classification criteria (ACR/EULAR2017) in 123 patients with idiopathic…
Abstract Number: 2296 • 2018 ACR/ARHP Annual Meeting
Novel Classification of Idiopathic Inflammatory Myopathies Based on Distinctive Features and Autoantibodies: Analysis of 67 Korean Patients
Sang Wan Chung¹, Su-Jin Yoo², Seong-Wook Kang³, In-Seol Yoo³, Seung-Cheol Shim³, Mihye Kwon⁴, Chung-Il Joung⁴, Jinhyun Kim⁵, Seung-Jae Hong¹ and Yeon-Ah Lee⁶, ¹Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea, Republic of (South), ²Departmen of Internal medicine, Chungnam National University School of Medicine, Daejeon, Korea, Republic of (South), ³Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea, Republic of (South), ⁴Department of Internal Medicine, Konyang University hospital, Daejeon, Korea, Republic of (South), ⁵Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea, Republic of (South), ⁶Rheumatology, Kyung Hee University Hospital, Seoul, Korea, Republic of (South)
Novel Classification Of Idiopathic Inflammatory Myopathies Based On Distinctive Features And Autoantibodies: Analysis Of 67 Korean PatientsBackground/Purpose: Since Bohan and Peter first described their diagnostic…
Abstract Number: 2297 • 2018 ACR/ARHP Annual Meeting
Performance of the New EULAR/Acr Classification Criteria for Idiopathic Inflammatory Myopathies (IIM) in a Large Monocentric IIM Cohort
Simone Barsotti^1,2, Valérie Leclair^3,4, Antonella Notarnicola^5,6, Luise Ekholm^3,4, Lara Dani^3,4, Maryam Dastmalchi^3,4 and Ingrid E. Lundberg⁶, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Department of Medical Biotechnologies, University of Siena, Siena, Italy, ³Department of Medicine, Division of rheumatology, Solna, Sweden, ⁴Kaolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁵Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁶Department of Medicine, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Patients with IIM have been classified mainly according to Bohan and Peter (B&P) criteria, proposed in 1975. In 2017 the new EULAR/ACR criteria were…
Abstract Number: 2298 • 2018 ACR/ARHP Annual Meeting
Developing a Classification Criteria for Cutaneous Dermatomyositis Utilizing the Delphi Technique
Josef Concha¹, Victoria P. Werth¹, Joseph F. Merola², David Fiorentino³, Jan Dutz⁴, Manabu Fujimoto⁵, Mark Goodfield⁶, Chia-Chun Ang⁷, Filippa Nyberg⁸ and Beatrix Volc-Platzer⁹, ¹University of Pennsylvania, Philadelphia, PA, ²Clinical Unit for Research Innovation & Trials, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Dermatology, Stanford University School of Medicine, Stanford, CA, ⁴Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada, ⁵University of Tsukuba, Faculty of Medicine, Department of Dermatology, Tsukuba, Japan, ⁶Leeds General Infirmary, Leeds, United Kingdom, ⁷Changi General Hospital, Singapore, Singapore, ⁸Karolinska Institute, Solna, Sweden, ⁹Wiener Krankenanstaltenverbund, Vienna, Austria
Background/Purpose: The new European League Against Rheumatism / American College of Rheumatology (EULAR / ACR) classification criteria for inflammatory myopathies are able to identify patients…
Abstract Number: 2299 • 2018 ACR/ARHP Annual Meeting
Subgroup Analysis of the Effect of Denosumab Compared with Risedronate on Percentage Change in Lumbar Spine Bone Mineral Density at 24 Months in Glucocorticoid-Treated Individuals
Kenneth Saag¹, Nicola Pannacciulli², Piet Geusens³, Jonathan D. Adachi⁴, Eric Lespessailles⁵, Jorge Malouf⁶, Bente Langdahl⁷, Peter W. Butler², Xiang Yin² and Willem F. Lems⁸, ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵University Hospital Orleans, Orleans, France, ⁶Hospital San Pablo, Barcelona, Spain, ⁷Aarhus University, Aarhus, Denmark, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: We previously demonstrated that denosumab increased lumbar spine and total hip bone mineral density (BMD) significantly more than risedronate at 12 and 24 months…
Abstract Number: 2300 • 2018 ACR/ARHP Annual Meeting
Compliance with Screening and Supplementation Guidelines for Glucocorticoid-Induced Osteoporosis, How Bad Did We Do This Time?
John Zawidniak¹ and John Waterman², ¹Rheumatology, University of Connecticut, Farmington, CT, ²Rheumatology, Connecticut VA Healthcare System, Newington, CT
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a well-established and well-studied phenomenon that is a sequela of the treatment of many inflammatory diseases. Many studies over the…
Abstract Number: 2301 • 2018 ACR/ARHP Annual Meeting
Trend of Osteoporosis and Osteoporotic Fragility Fractures Among Select Autoimmune Rheumatologic Diseases: Results from National Inpatient Sample
Rashmi Dhital¹, Theresa Lynn², Pragya Shrestha³, Sijan Basnet⁴, Prakash Paudel⁵, Priyadarshani Sharma², Paras Karmacharya⁶ and Dilli Poudel⁷, ¹Reading Hospital-Tower Health System, West Reading, PA, ²Reading Hospital, West Reading, PA, ³Internal medicine, Reading Hospital-Tower Health System, West Reading, PA, ⁴Internal Medicine, Reading Hospital, West Reading, PA, ⁵Internal Medicine, Berkshire Medical Center, Pittsfield, MA, ⁶Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁷Internal Medicine, Reading Hospital-Tower Health System, WEST READING, PA
Background/Purpose: Rheumatologic diseases (RDs) have been associated with an increased risk of osteoporosis (OP) and osteoporotic fractures, however, most patients do not receive diagnosis and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].